XML 20 R8.htm IDEA: XBRL DOCUMENT v3.21.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended 12 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Cash flows from operating activities          
Net income (loss) $ 51,868 $ (57,717) $ 85,279 $ (56,593)  
Adjustments to reconcile net income (loss) to net cash (used for) provided by operating activities:          
Net unrealized (gain) loss     (7,499) 54,661  
Change in fair value of contingent consideration     44,900 0  
Stock-based compensation     60,250 44,634  
Depreciation and amortization     202,231 195,022  
Loss on sale of subsidiary 0 46,362 0 46,362  
Gain on sale of equity investment     (3,617) 0  
Debt restructuring and debt issuance cost amortization     13,315 9,464  
Deferred tax benefit     (8,829) (16,514)  
Provision for credit losses 14,127 12,283 32,148 66,851  
Changes in operating assets and liabilities, net of effects of acquisitions:          
Accounts receivable and securitized accounts receivable     (1,138,233) 406,095  
Prepaid expenses and other current and other long-term assets     13,212 (892)  
Accounts payable     517,455 (48,528)  
Accrued expenses and restricted cash payable     211,855 46,367  
Income taxes     (12,363) 23,697  
Other current and other long-term liabilities     (20,459) 3,830  
Net cash (used for) provided by operating activities     (10,355) 774,456  
Cash flows from investing activities          
Purchases of property, equipment and capitalized software     (55,484) (59,651)  
Cash paid on sale of subsidiary     0 (15,957)  
Cash proceeds from sale of equity investment     3,117 0  
Distribution of equity investment     0 837  
Purchases of investment securities     (250) (356)  
Maturities of investment securities     130 169  
Acquisitions, net of cash and restricted cash acquired     (558,247) 0  
Net cash used for investing activities     (610,734) (74,958)  
Cash flows from financing activities          
Repurchase of share-based awards to satisfy tax withholdings     (23,012) (9,271)  
Proceeds from stock option exercises     43,744 4,227  
Net change in deposits     558,042 (163,036)  
Net activity on other debt     21,500 (86,916)  
Borrowings on revolving credit facility     1,176,300 300,000  
Repayments on revolving credit facility     (962,900) (300,000)  
Borrowings on term loans     112,819 0  
Repayments on term loans     (47,824) (48,458)  
Redemption of Notes     (400,000) 0  
Proceeds from issuance of convertible notes     0 299,150  
Proceeds from issuance of common stock     0 90,000  
Debt issuance costs   (570) (8,934) (11,836)  
Net change in securitized debt     8,004 (31,594)  
Net cash provided by financing activities     477,739 42,266  
Effect of exchange rates on cash, cash equivalents and restricted cash     (24,037) (7,908)  
Net change in cash, cash equivalents and restricted cash     (167,387) 733,856  
Cash, cash equivalents and restricted cash at beginning of period [1]     1,329,653 981,381 $ 981,381
Cash, cash equivalents and restricted cash at end of period [1] 1,162,266 1,715,237 1,162,266 1,715,237 1,329,653
Supplemental disclosure of non-cash investing and financing activities          
Capital expenditures incurred but not paid     5,451 2,087  
Non-cash contribution from non-controlling interest     12,457 0  
Deferred cash consideration as part of asset acquisition     47,408 0  
Contingent consideration as part of asset acquisition     27,200 0  
Promissory note received in exchange for sale of equity investment     500 0  
Amounts included in loss on sale of subsidiary but not paid     0 6,514  
Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents [Roll Forward]          
Cash and cash equivalents at beginning of period     852,033 810,932 810,932
Restricted cash at beginning of period     477,620 170,449 170,449
Cash, cash equivalents and restricted cash at beginning of period [1]     1,329,653 981,381 981,381
Cash and cash equivalents at end of period 533,830 1,521,622 533,830 1,521,622 852,033
Restricted cash at end of period 628,436 193,615 628,436 193,615 477,620
Cash, cash equivalents and restricted cash at end of period [1] $ 1,162,266 $ 1,715,237 $ 1,162,266 $ 1,715,237 $ 1,329,653
[1] The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within our condensed consolidated balance sheets to amounts within our condensed consolidated statements of cash flows.